Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NRSN Stock Forecast 2025-2026
$1.04
Current Price
$25.04M
Market Cap
Buy 1
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to NRSN Price Targets
+618.4%
To High Target of $7.50
+618.4%
To Median Target of $7.50
+618.4%
To Low Target of $7.50
NRSN Price Momentum
-2.8%
1 Week Change
-1.9%
1 Month Change
-11.9%
1 Year Change
-13.3%
Year-to-Date Change
-30.4%
From 52W High of $1.50
+103.9%
From 52W Low of $0.51
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching NeuroSense (NRSN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on NRSN and similar high-potential opportunities.
Latest NRSN Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, NRSN has a neutral consensus with a median price target of $7.50 (ranging from $7.50 to $7.50). Currently trading at $1.04, the median forecast implies a 618.4% upside. This outlook is supported by 1 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from James Molloy at Alliance Global Partners, projecting a 618.4% upside. Conversely, the most conservative target is provided by James Molloy at Alliance Global Partners, suggesting a 618.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NRSN Analyst Ratings
1
Buy
1
Hold
0
Sell
NRSN Price Target Range
Low
$7.50
Average
$7.50
High
$7.50
Current: $1.04
Latest NRSN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NRSN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 16, 2024 | Maxim Group | Naz Rahman | Hold | Downgrade | $0.00 |
| Jul 17, 2023 | Alliance Global Partners | James Molloy | Buy | Initiates | $7.50 |
| Jan 7, 2022 | Maxim Group | Naz Rahman | Buy | Initiates | $7.00 |
Neurosense Therapeutics Ltd. (NRSN) Competitors
The following stocks are similar to NeuroSense based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Neurosense Therapeutics Ltd. (NRSN) Financial Data
Neurosense Therapeutics Ltd. has a market capitalization of $25.04M with a P/E ratio of -1.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -2,478.2%.
Valuation Metrics
Market Cap
$25.04M
Enterprise Value
$21.11M
P/E Ratio
-1.9x
PEG Ratio
-1.9x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+13.5%
Current Ratio
2.2x
Debt/Equity
2.8x
ROE
-2,478.2%
ROA
-159.5%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Neurosense Therapeutics Ltd. (NRSN) Business Model
About Neurosense Therapeutics Ltd.
What They Do
Develops innovative treatments for neurodegenerative diseases.
Business Model
Neurosense Therapeutics operates as a clinical-stage biotechnology firm focused on research and development of drugs for neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's. The company makes money by advancing its drug candidates through clinical trials and seeking partnerships with academic institutions and research organizations to validate its approaches and enhance its scientific credibility.
Additional Information
Neurosense aims to address unmet medical needs in the field of neurodegeneration, positioning itself as a key player in biotechnology. The company strives to deliver breakthroughs that could improve the quality of life for millions of patients affected by these debilitating conditions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
17
CEO
Mr. Alon Ben-Noon
Country
Israel
IPO Year
2021
Website
www.neurosense-tx.comNeurosense Therapeutics Ltd. (NRSN) Latest News & Analysis
Latest News
Quick Summary
NeuroSense Therapeutics has selected a global CDMO for manufacturing scale-up, aiming for rapid commercialization in a projected $100-150 million Canadian market.
Why It Matters
NeuroSense's selection of a global CDMO and manufacturing scale-up accelerates its path to market, potentially unlocking significant revenue in a projected $100-150M Canadian market.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
NeuroSense Therapeutics outlines Phase 3 timeline for PrimeC in ALS and updates on Canadian regulatory pathway and partnership talks with a global pharmaceutical company.
Why It Matters
The update on Phase 3 trials and regulatory progress, along with potential partnerships, signals growth prospects for NeuroSense Therapeutics, impacting investor confidence and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
New miRNA findings presented at AAN highlight key biological mechanisms of PrimeC's clinical benefits in ALS, potentially impacting its market value and investor interest.
Why It Matters
The new miRNA findings on PrimeC's clinical benefits in ALS could enhance its market potential, influencing stock performance and attracting investor interest in biotech advancements.
Source: PRNewsWire
Market Sentiment:
Neutral
NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates
1 month ago
Quick Summary
NeuroSense Therapeutics' Phase 2b study of PrimeC in ALS showed slowed disease progression. Partnership talks ongoing for a Phase 3 trial, set to begin in 2025, aligned with FDA guidelines.
Why It Matters
Successful Phase 2b results for PrimeC in ALS may enhance NeuroSense’s market position and attract investment, while potential FDA alignment boosts commercialization prospects.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
NeuroSense Therapeutics will present new clinical and microRNA data at the General Neurology and Late Breaker sessions, as announced on April 4, 2025.
Why It Matters
New clinical and microRNA data from NeuroSense could indicate breakthroughs in neurology, potentially impacting stock performance and investor sentiment in biotech markets.
Source: PRNewsWire
Market Sentiment:
Neutral
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
1 month ago
Quick Summary
NeuroSense Therapeutics (NASDAQ: NRSN) is advancing the commercialization of PrimeC in Canada, having been invited to a pre-NDS meeting by Health Canada for potential ALS treatment approval.
Why It Matters
Progress in commercializing PrimeC for ALS may enhance NeuroSense's market position and attract investor interest, impacting stock performance and future funding opportunities.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About NRSN Stock
What is Neurosense Therapeutics Ltd.'s (NRSN) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Neurosense Therapeutics Ltd. (NRSN) has a median price target of $7.50. The highest price target is $7.50 and the lowest is $7.50.
Is NRSN stock a good investment in 2025?
According to current analyst ratings, NRSN has 1 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NRSN stock?
Wall Street analysts predict NRSN stock could reach $7.50 in the next 12 months. This represents a 618.4% increase from the current price of $1.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Neurosense Therapeutics Ltd.'s business model?
Neurosense Therapeutics operates as a clinical-stage biotechnology firm focused on research and development of drugs for neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's. The company makes money by advancing its drug candidates through clinical trials and seeking partnerships with academic institutions and research organizations to validate its approaches and enhance its scientific credibility.
What is the highest forecasted price for NRSN Neurosense Therapeutics Ltd.?
The highest price target for NRSN is $7.50 from James Molloy at Alliance Global Partners, which represents a 618.4% increase from the current price of $1.04.
What is the lowest forecasted price for NRSN Neurosense Therapeutics Ltd.?
The lowest price target for NRSN is $7.50 from James Molloy at Alliance Global Partners, which represents a 618.4% increase from the current price of $1.04.
What is the overall NRSN consensus from analysts for Neurosense Therapeutics Ltd.?
The overall analyst consensus for NRSN is neutral. Out of 2 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $7.50.
How accurate are NRSN stock price projections?
Stock price projections, including those for Neurosense Therapeutics Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 4:26 AM UTC